Novi Tham
@slumberbell
HF Cardiologist🩺|Director of CardioOncology program🫀|CMP❤️🩹|PH🫁|@apsc_office young|#SoMe editorial team #JACCHF|Cellist noobz 🎻|loves photography📸
ID:1448542366315335685
14-10-2021 06:53:30
2,2K Tweets
953 Followers
755 Following
‼️ don’t miss the first meeting on location from Young@Heart 💛
📅 Wednesday June 5th
⏰ 11:00-13:00h
📍 UMCG
More information and registration ⬇️
UMCG Cardiology Research Institute Peter-Paul Zwetsloot Anke Smits Iris Beldhuis Marlene Vijver Kevin Damman Nils Bömer Peter van der Meer Adriaan Voors
📣 Register NOW for the First #HFAJournalClub 📰
The PUSH-AHF Trial
🗓️ 5 June 2024
🕖 18:00 CET
📩 SEND YOUR QUESTIONS before the event
Made by and for the #HFA_Young
🔗esc365.escardio.org/event/1635
#HFA_ESC European Society of Cardiology #HFA_Young
Jozine ter Maaten Chris Kapelios Henrike Arfsten Antonio Cannata'
Tune in JACC Journals #JACCAdvancesPulse for valuable insights from Erin D. Michos, M.D. & ambarish on
🎯 Role of #Cardiometablic multispecialty clinics in current #CVD landscape
🎧👉 jacc.org/jacc-advances/…
Candice Silversides Sadeer Al-Kindi, MD Bailey Ann Estes Dr. Martha Gulati ♥️🫀❤️🩹🇨🇦 American College of Cardiology
Safety of #daratumumab monotherapy in newly diagnosed Stage 3b #AL presented by Prof. Efstathios Kastritis #ANDROMEDA excluded Mayo Stage 3b patients. #ISA_2024 University of Athens The International Society Of Amyloidosis
📍6 month OS rate = 65%
📍>50% achieved VGPR
📍27.5% had cardiac response at 6 months
In an analysis of VICTORIA, Dr. Robert Mentz, MD shows #vericiguat does not reduce *total* HF hospitalization or CV death in #HFrEF . Mortality was high following HF hospitalization. bit.ly/3UYEL32
#JACCHF #HeartFailure #GDMT
The mortality rate in FLOW was the highest of any recent CKD outcome trials
And highlighting the potential for combination therapy to substantially improve outcomes
Independent commentary by Christoph Wanner
#era24 ERA - European Renal Association
New #ESCTVToday episode 🤗
Michael Boehm discusses the use of beta-blockers in patients after myocardial infarction. What are the key findings of the REDUCE-AMI trial and the most important implications for current clinical practice? bit.ly/4aAav4n
#CVD #MI #cardiology
Your one-stop hub for #amyloidosis and #CardioOnc is finally here! The #JACCCardioOnc Amyloidosis Hub is ready to inspire, inform, and invigorate with cutting-edge science and evidence-based care. bit.ly/3X1C6sh
The International Society Of Amyloidosis The Penn Thalheimer Center for Cardio-Oncology
Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the #HFA of the ESC
onlinelibrary.wiley.com/doi/full/10.10… #CardioEd
#EJHF European Society of Cardiology Journals EJHF Editor-in-Chief Amina Gianluigi Savarese Magdy Abdelhamid Ekaterini Lambrinou💙
In patients w #ChronicKidneyDisease &Type 2 #Diabetes :
#Semaglutide ⬇️ the primary outcome of kidney events, composite ESKD, >50% reduction in eGFR, or CV death by 24% vs placebo (331 vs. 410 events; HR 0.76; 95% CI, 0.66 to 0.88; P=0.0003.
#GLP1RA nejm.org/doi/full/10.10…
Amazing talk by Tariq Ahmad MD MPH !!! Some key slides that stuck with me... DeBakey CV Education - World Class CV Training #CardioX #CardioTwitter #HeartFailure #HFA_young
youtube.com/watch?v=QNdt0Q…